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ABSTRACT 19	  
Background. Usually IgM serology is not sufficiently specific to confirm Zika infection. 20	  
However, since IgM does not cross the placenta it may be a good marker of infection in 21	  
neonates.  22	  
Methods. We tested blood from 42 mothers and neonates with microcephaly; and collected 23	  
cerebrospinal fluid (CSF) from 30 neonates. Molecular assays were performed for ZIKV, 24	  
DENV and CHIKV; ELISA-IgM and PRNT for ZIKV and DENV. No control neonates 25	  
without microcephaly were evaluated. 26	  
Results. In neonates, 38/42 (90.5%) were ZIKV-IgM positive, all 30 CSF were positive and 27	  
considering blood or CFS all 42 neonates were ZIKV-IgM positive. ZIKV-IgM results were 28	  
higher in CSF (median 14.9 [9.3-16.4]) than in serum (median 8.9 [2.1-20.6]) p=0.0003. All 29	  
ZIKV-IgM positive results in the neonates were confirmed by the presence of neutralising 30	  
antibodies (NAb). ZIKV-primary infection had NAb to ZIKV only; secondary 31	  
Flavivirus/ZIKV-infected cases had high titter of NAb to ZIKV; mothers median was 2,072 32	  
(232-12,980) and neonate 2,730 (398-12.980), p <0.0001; CSF median was 93 (40-578), 33	  
p<0.0001.  34	  
Conclusion. Detection of Zika IgM in the neonate is confirmatory of congenital Zika and in 35	  
the CSF of neurologic infection. Therefore, we recommend testing of Zika IgM in neonates 36	  
suspected of congenital Zika and PRNT in equivocal cases.  37	  
Keywords: Zika virus, microcephaly, congenital Zika, Anti-ZIKV IgM, ZIKV antibodies.  38	  
 39	  
 40	  
 41	  
 42	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INTRODUCTION   44	  
Zika virus (ZIKV) was first detected in Northern Brazil in March 2015 in the serum of 45	  
patients with a dengue-like illness. Phylogenetic analysis demonstrated that the Brazilian 46	  
strain belonged to the Asian lineage and was highly related to a ZIKV isolate from French 47	  
Polynesia [1]. By the end of year, the virus had spread to 19 of the 27 Brazilian states [2] and 48	  
by April 2016 to 34 countries and territories in America. An epidemic of microcephaly started 49	  
in Brazil in October, six to seven months after health authorities confirmed ZIKV 50	  
transmission in the country; and it was declared a Public Health Emergency of International 51	  
Concern by the World Health Organization (WHO) in February 1st, 2016 [3]. 52	  
Based on the growing evidence that ZIKV was the etiological agent of the microcephaly, as 53	  
well as other manifestation of zika syndrome [4-10], the causal link between ZIKV and 54	  
microcephaly was finally recognized [11]. The hesitancy to accept causation in the presence 55	  
of much epidemiological circumstantial evidence was related to the difficulty of laboratory 56	  
confirmation in affected infants.  57	  
Laboratory diagnosis of ZIKV is challenging. In an outbreak of ZIKV in Yap Island, 58	  
Federated States of Micronesia, in 2007, Lanciotti and colleagues [12] analysed serum 59	  
samples from ZIKV-infected patients by using serological assays, such as detection of IgM 60	  
antibodies by IgM-capture enzyme-linked immunosorbent assay (ELISA) and plaque 61	  
reduction neutralization test (PRNT) to diagnose and evaluate the extent of cross-reactivity 62	  
among flaviviruses. They found marked cross-reactivity with other flaviviruses, mainly in 63	  
patients where the ZIKV was the secondary flavivirus infection; an accurate diagnosis 64	  
required combining serologic data to ZIKV detection by molecular methods [12].  65	  
The current recommendation for routine diagnosis of ZIKV infection include detection of the 66	  
viral nucleic acid by reverse transcription polimerase chain reaction (RT-PCR), detection of 67	  
specific IgM antibodies by ELISA and PRNT for confirmation of positive IgM result and 68	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exclusion of other flaviviruses [13,14]. The cross-reactivity of flavivirus antibodies is 69	  
accepted as the main challenge in the interpretation of serologic test results, especially when 70	  
the PRNT is not available [12-14].  Laboratory diagnosis is an essential tool for research and 71	  
for public health prevention measures; thus, validation of commercial kits and a better 72	  
understanding of the performance of currently available kits for detection of IgM antibodies is 73	  
an urgent priority to diagnose ZIKV infection.  74	  
In this study, we compared results of serologic testing (ELISA) for ZIKV-IgM, dengue virus 75	  
(DENV) IgM and IgG antibodies and of ZIKV and DENV neutralising antibodies in serum 76	  
from 42 mothers and their neonates born with microcephaly.  The levels of ZIKV-specific 77	  
IgM and neutralising antibodies in the CSF samples of 30 neonates were also assessed.  78	  
 79	  
METHODS 80	  
Population, study settings and ethic issues  81	  
From 21 to 30 October 2015 we collected samples from 42 neonates with microcephaly and 82	  
from their mothers. Neonates were born between September 5 and October 27, 2015, in 83	  
hospitals located in the Metropolitan Region of Recife, Pernambuco State, Brazil. These cases 84	  
constituted the very first of microcephaly identified in this outbreak. No control neonates 85	  
without microcephaly born in this period were included in this study. Microcephaly was 86	  
defined as neonatal occipitofrontal circumference ≥ 2 SD below the mean for gestational age 87	  
and sex of the new born at birth [15]. We conducted this investigation as part of the routine 88	  
epidemiologic and laboratory surveillance and as such, ethical committee approval was not 89	  
required. However, we did collect mother´s written informed consent to participate.  90	  
 91	  
Sample collection and processing  92	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We collected blood from 42 mothers and neonates and CSF from 30 of the neonates; 93	  
specimens were sent to the Department of Virology at Fiocruz Pernambuco, under 94	  
refrigeration. Blood samples were spun down for 10 minutes at 1500 g and serum was stored 95	  
at –80º C. CSF samples were frozen at –80º C without processing. We carried out molecular 96	  
diagnostic assays for ZIKV, DENV and chikungunya virus (CHIKV) in the neonate 97	  
specimens (serum and CSF). Serologic test were performed for DENV and ZIKV in all 98	  
samples.  99	  
 100	  
Molecular assays 101	  
Serum and CSF were tested by RT-PCR or, real-time RT-PCR (qRT-PCR) for detection of 102	  
ZIKV, DENV and CHIKV. Viral RNA was extracted using the QIAamp Viral RNA Mini Kit 103	  
(Qiagen, Valencia, CA) according to the manufacturer’s instructions. RT-PCR was performed 104	  
for ZIKV using previously described methods with minor modifications [16] in which two 105	  
steps RT-PCR was used (cDNA synthesis followed by the PCR) instead of one step protocol. 106	  
For DENV a well-established RT-PCR protocol was employed [17]; for CHIKV, the qRT-107	  
PCR was performed according to Lanciotti et al [18].  108	  
 109	  
Serologic assays  110	  
DENV IgM and IgG antibodies - Serum samples from mothers and neonates were first tested 111	  
for dengue IgM and IgG antibodies detection using the commercial kits: Dengue IgM-capture 112	  
ELISA and Dengue IgG capture ELISA (PANBIO, Inverness Medical Innovations Australia 113	  
Pty Ltd), following the manufacturer´s guidelines.  114	  
 115	  
ELISA for ZIKV and DENV- Serum and CSF were tested by IgM antibody capture ELISA 116	  
using the protocol [12] and reagents provided by the Centers for Disease Control and 117	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Prevention (CDC, Fort Collins, CO, EUA). Samples were tested in parallel with ZIKV and 118	  
DENV antigens to investigate cross-reactivity; reagents were previously tittered and diluted 119	  
as appropriated. Briefly, plates were coated with 75µl of goat anti-human IgM (Kirkegaard 120	  
and Perry Laboratories, USA) in carbonate/bicarbonate (pH 9.6) and incubated overnight at 4o 121	  
C. After blocking with PBS pH 7.2, 5% non-fat dry-milk /0.05% tween 20, for 30 minutes at 122	  
room temperature (RT) and washing (done after each step), 50µl of serum samples diluted 123	  
1/400 in PBS pH 7.2, 0.05% Tween 20 and CSF undiluted; negative (pooled flavivirus-124	  
negative serum) and positive (CDC humanized 6B6C-1 pan-flavivirus) controls, were added 125	  
and incubated at 37oC for 1 hour. Viral Zika antigen (CDC Vero E6 derived, inactivated 126	  
ZIKV antigen; Normal antigen (CDC Vero E6 derived, mock-infected normal antigen)  and 127	  
dengue antigen: mixture of the four serotypes (Evandro Chagas Institute, Brazil) were added 128	  
to each sample (50µl) and incubated overnight at 4oC. Detecting antibody conjugate 129	  
(Horseradish peroxidase conjugated monoclonal antibody 6B6C-1, CDC) diluted in blocking 130	  
buffer was added: incubation for 1 hour at 37oC. The substrate TMB (3,3'5, 5' 131	  
tetramethylbenzidine base, Becton Dickson, USA) was added; after 10 minutes incubation at 132	  
RT the reaction was stopped with 1NH2SO4 solution and the optical density (OD) read at 450 133	  
nm. The ratio (P/N) was calculated as follows: Mean OD of the test sample reacted on viral 134	  
antigen (P) divided by the Mean OD of the negative control reacted on viral antigen (N). P/N 135	  
value <2.0 was negative; >3.0 was positive; and between 2.0 and 3.0 was considered 136	  
equivocal. If the sample showed some degree of cross-reactivity it was considered ZIKV-IgM 137	  
positive only when the Zika P/N was, at least, twice higher than the dengue P/N. 138	  
 139	  
Plaque Reduction Neutralization Test – PRNT50 was performed following a modified 140	  
protocol previously described elsewhere [19].  Briefly, tests were carried out on Vero cells 141	  
seeded at the density of 300,000 cells/mL using 24-well plates. The assay was performed after 142	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serial dilution of serum (inactivated 30 minutes at 56º C) and CSF (1/20 to 1/20,480) and 143	  
incubation of 100 PFU challenge viruses, previously tittered. The assay was carried out using 144	  
viruses isolated in the State of Pernambuco: ZIKV (Brazil-PE243/2015); DENV-1 (BR-145	  
PE/97-42735), DENV-2 (BR-PE/95-3808), DENV-3 (BR-PE/02-95016) and DENV-4 (BR-146	  
PE/12-008), molecularly characterized. Neutralising antibody titters were determined by 147	  
using a PRNT with a 50% cut-off value (PRNT50); ZIKV and DENV serotype-specific 148	  
antibodies titters were calculated using a four-parameter non-linear regression. 149	  
 150	  
Data preparation and analysis - The medians values were calculated using Wilcoxon test 151	  
for pared samples. DENV serotype-specific and ZIKV neutralising antibodies titters 152	  
(PRNT50) were estimated using a four-parameter non-linear regression. Statistical analysis 153	  
was performed using Graph Pad Prism, version 6.0e. 154	  
Classification of immunological response: Primary-ZIKV infection was considered present if 155	  
neonate/mother had a negative DENV-IgG and a positive ZIKV-IgM confirmed by a PRNT 156	  
positive to ZIKV only; Secondary Flavivirus/ZIKV infection was confirmed if the neonate 157	  
had positive DENV-IgG, positive ZIKV-IgM, PRNT positive to ZIKV and to any DENV 158	  
serotype. We present results for all 42 mother-neonate pairs in the text, and for the 30 in 159	  
which the neonate had a CSF sample in the tables.  160	  
 161	  
RESULTS 162	  
Mothers were young (age 15 – 38 years), 13 were < 20 years old (31%); 21 (50% [20 to 29 163	  
years]) and 8 (19%) from 30 to 38. Twenty-six of 42 mothers (62%) reported rash during 164	  
pregnancy; 23 in the first trimester and three in the second trimester; fever was reported only 165	  
by 12 of 26 mothers with rash. Thirteen of 42 (31%) denied any symptoms consistent with 166	  
viral infection during pregnancy.  167	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ZIKV, DENV and CHIKV viral genomes were not detected in serum or in CSF samples by 168	  
RT-PCR and/or qRT-PCR.  169	  
 None of the 42 mother-neonate paired serum samples had IgM antibodies to DENV; 170	  
however, 83.3% of the mothers and their babies had DENV-IgG antibodies in serum, in the 171	  
remaining 16.7% (7/42) DENV-IgG was negative; these results were confirmed by PRNT.  172	  
In serum, 13 of 42 mothers (31%) had ZIKV-IgM antibodies; of the remaining mothers, 29/42 173	  
(69%) were negative.  174	  
In neonates, 38/42 (90.5%) of serum were positive for ZIKV-IgM antibodies; the remaining 175	  
four of 42 (9.5%) samples were negative. Importantly, specific ZIKV-IgM antibodies were 176	  
detected in all 30 samples of CSF obtained from neonates with microcephaly.    177	  
Results of the serologic testing for the sub-set of 30 mother-neonate pairs in which the 178	  
neonate had CSF collected are shown in the tables. Table 1 and 3 present results for the pairs  179	  
where ZIKV would be a primary flavivirus infection (eg those without DENV IgG in serum) 180	  
and tables 2 and 4 for those where ZIKV would be the secondary infection (for pairs with 181	  
DENV-IgG in serum).  182	  
Table 1 presents results of DENV-IgG, ZIKV-IgM and DENV-IgM in seven mother/neonate 183	  
pairs without DENV-IgG in serum (primary ZIKV infection). IgM antibody response in 184	  
primary ZIKV–infected neonates was specific for ZIKV in six of seven (85.7%) CSF tested. 185	  
In one (case 12), ZIKV-IgM antibodies cross-reacted with dengue; case 21 had a monotypic 186	  
ZIKV-IgM response in CSF (P/N 15.6) but IgM result was equivocal in serum (P/N 2.1) 187	  
(Table 1).    188	  
Table 2 shows results of 23 mother-neonate pairs in which ZIKV would be a secondary 189	  
flavivirus infection: of these, 11 mothers (47.8%) were positive for ZIKV-IgM. Among 190	  
neonates, ZIKV-IgM antibodies were detected in all 23 CSF samples and in 21 serum samples 191	  
(91.3%). A monotypic ZIKV-IgM antibody response was present in CSF in 18 samples 192	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among the 20 cases; all demonstrated low levels of cross-reactive IgM as shown by a dengue 193	  
P/N value in the equivocal range (2.0 – 3.0).  194	  
Presence of ZIKV-IgM in CSF and in serum was concordant in 95.6%. Among the 30 CSF 195	  
results with ZIKV-IgM, there were 24 with monotypic responses and only six cross-reacted 196	  
with DENV. Figure 1A shows ZIKV-IgM results in CSF (median 14.9 [9.3-16.4]) and in sera 197	  
(median 8.9 [2.1-20.6]) p=0.0003.   198	  
A subset of the suspected ZIKV-infected neonates for whom paired serum and CSF 199	  
specimens had been collected was analysed by using PRNT50 to search for specific ZIKV and 200	  
DENV neutralising antibodies and to evaluate the extent of cross reactivity to related 201	  
flavivirus. 202	  
Table 3 shows the PRNT50 results for the seven primary ZIKV infection cases. Mother and 203	  
neonate serum and CSF samples had specific neutralising antibodies only for ZIKV, 204	  
confirming the ELISA results for ZIKV-IgM presented in the Table 1.  PRNT50 results also 205	  
showed that the neutralising antibody response among primary ZIKV–infected patients was 206	  
highly specific.  207	  
All 18 secondary ZIKV-infected cases (mothers and neonates) (Table 4), had high titter of 208	  
neutralising antibodies to ZIKV; for the mothers, the median was 2,072 (range 232-12,980) 209	  
and for the neonate the median was 2,730 (range 398-12.980), p <0.0001; in CSF the 210	  
neutralising antibodies titter was lower than in serum. In CSF, the median was 93 (range 40-211	  
578), p<0.0001 (Figure 1B). Presence of neutralising antibodies to DENV serotypes in serum 212	  
of the neonates was similar to the mother. However, in CSF samples, the neutralising 213	  
antibodies were exclusively to ZIKV. There was a remarkably good concordance between 214	  
anti-ZIKV-IgM results in CSF and serum of neonates with the PRNT results.  215	  
As for neutralising antibodies for DENV, 11 had for DENV-3 and DENV-4; four for DENV-216	  
4; one for DENV-3 and one case to all DENV serotypes. Of seven mothers with negative 217	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serology for DENV, 28.6% had ZIKV-IgM antibodies in serum; of 23 mothers who were 218	  
positive for DENV, 11 (47.8%) had ZIKV-IgM antibodies in serum.  219	  
 220	  
DISCUSSION 221	  
It is known that IgM antibodies to DENV can be detected at least 90 days after the onset of 222	  
symptoms [20], but it is not known how long ZIKV-IgM antibodies remain detectable after 223	  
infection, in blood and in cerebrospinal fluid of newborns with microcephaly.  224	  
Based on the fact that 23 of 26 mothers that reported rash indicated that the rash was in the 225	  
first trimester of pregnancy, it is likely that Zika infection would have occurred at least six 226	  
months prior birth. Although, we cannot be sure of when the infections have occurred, it is 227	  
possible that ZIKV-IgM antibodies would remain longer than 90 days; prospective studies are 228	  
needed to elucidate that.   229	  
Surprisingly, none of the mothers in this study reported presence of rash in the third trimester 230	  
of pregnancy; it is possible that 31% of them experienced asymptomatic Zika infection.   231	  
There is evidence that the virus can persist for long time in the central nervous system (CNS) 232	  
of foetuses [6], however, we could not detect ZIKV RNA in the neonate CSF samples.  233	  
In our study, the specimens that were ZIKV-IgM positive and DENV-IgM negative by ELISA 234	  
were initially considered as a presumptive recent ZIKV infection; and they were all confirmed 235	  
by the PRNT. We found that 90.5% and 97% of the neonates had ZIKV-IgM antibodies in 236	  
serum or in CSF, respectively; indicating that the embryo or the foetal brain were exposed.   237	  
In the ZIKV epidemic in Yap State, Micronesia, secondary flavivirus–infected patients had a 238	  
higher degree of serologic cross-reactivity with other flaviviruses than primary 239	  
flavivirus/ZIKV–infected patients [12]. This was much less marked in the neonates in our 240	  
study; serologic cross-reactivity with DENV was observed in only five of 23 secondary cases 241	  
(21.7%) and only one (14.3%) among our seven ZIKV primary cases. Antibody response to 242	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ZIKV was monotypic in 78.3% (18/23) of the secondary flavivirus/ZIKV infection cases. The 243	  
most probable is that IgM does not cross the placental barrier, at least to a significant degree, 244	  
and since these samples were collected in the perinatal period these neonates, probably, have 245	  
not been directly exposed to other flaviviruses, except for ZIKV in uterus. Moreover, the IgM 246	  
in the CSF indicate the presence of antigen specific B-cell in the brain and high specificity in 247	  
the IgM capture ELISA. In contrast, the neonates had maternal IgG and hence also the anti-248	  
DENV-IgG; for neonates IgG based diagnostic has low specificity.  249	  
Consistently with findings in Yap study, our PRNT results have shown higher titters of 250	  
neutralising antibody to ZIKV, however, in contrast to the Yap study [12], in our study cross-251	  
reactivity among the two flaviviruses, ZIKV and DENV was not observed, although both 252	  
viruses are circulating in our region. In Pernambuco State, yellow fever vaccination is not 253	  
compulsory, the region is not at risk for sylvatic yellow fever virus (YFV), and as none of the 254	  
mothers were vaccinated against YFV this virus was not tested in the PRNT.    255	  
Neutralising antibody responses to DENV were mainly to DENV-3 and DENV-4 (only one 256	  
mother presented antibodies to DENV-1 and DENV-2 and one to all four serotypes). As the 257	  
mothers were young these findings reflect the epidemiological scenario of dengue circulation 258	  
in Pernambuco State in the last 30 years, with DENV-1 introduced in 1987, DENV-2 in 259	  
1994,and DENV-3 in 2002; DENV-3 predominated until DENV-4 introduction in 2010 [19-260	  
23].  261	  
Our study adds important evidence that supports the etiological relationship between ZIKV 262	  
infection of the CNS and microcephaly. We found that 97% of the microcephalic infants had 263	  
ZIKV-positive IgM in the CNS. Since IgM does not normally cross either the placenta or the 264	  
blood-brain barrier, detection of virus-specific IgM in the CSF is a significant diagnostic 265	  
finding, indicating that the neonate had a CNS ZIKV infection during pregnancy [23].  266	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Detection of neutralising antibodies to ZIKV in the neonates CSF samples corroborates the 267	  
ZIKV-IgM positive results and indicates that detection of ZIKV-IgM in the neonate blood or 268	  
CSF is a good diagnostic tool. The relevance of this study is that these were the first cases of 269	  
microcephaly identified in Recife, state of Pernambuco, in September 2015 that sparked the 270	  
investigation for the cause of the outbreak. Despite this study lacks control neonates samples 271	  
for comparison, our findings is another piece of evidence that suggest that the brain 272	  
abnormalities were a consequence of Zika congenital infection. Moreover, based on these 273	  
results we conclude that identification of anti-Zika IgM in the neonate serum during the 274	  
perinatal period is confirmatory of congenital Zika. Therefore, we recommend for testing anti-275	  
Zika IgM in neonates suspected of congenital Zika, and that the PRNT could be employed to 276	  
elucidate equivocal cases.  277	  
 278	  
Conflict of interest. None. 279	  
Acknowledgements. We are grateful to the Instituto Evandro Chagas, Ministry of Health, 280	  
Pará, Brazil; the Center for Disease Control and Prevention (CDC Fort Collins, CO, USA) 281	  
and the Pan American Health Organization and the Microcephaly Epidemic Research Group 282	  
(MERG) for their support.  283	  
 284	  
References 285	  
 286	  
1. Campos GS, Bandeira AC, Sardi SI. Zika Virus Outbreak, Bahia, Brazil. Emerg Infect 287	  
Dis 2015; 21: 1885-6. 288	  
2.  Chen LH, Hamer DH. Zika Virus: Rapid Spread in the Western Hemisphere. Ann 289	  
Intern Med 2016; 164:613-5. 290	  
	   13	  
3. WHO. WHO statement on the first meeting of the International Health Regulations 291	  
(2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in 292	  
neurological disorders and neonatal malformations 2016. 293	  
4. Schuler-Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A, 294	  
et al. Possible Association Between Zika Virus Infection and Microcephaly - Brazil, 295	  
2015. MMWR Morb Mortal Wkly Rep 2016; 65: 59-62. 296	  
5.  Martines RB, Bhatnagar J, Keating MK, Silva-Flannery L, Muehlenbachs A, Gary J, 297	  
et al. Notes from the Field: Evidence of Zika Virus Infection in Brain and Placental 298	  
Tissues from Two Congenitally Infected Newborns and Two Fetal Losses - Brazil, 299	  
2015. MMWR Morb Mortal Wkly Rep 2016; 65: 159-60. 300	  
6. Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, et al. Zika Virus 301	  
Associated with Microcephaly. N Engl J Med 2016; 374:951-8. 302	  
7. de Paula Freitas B, de Oliveira Dias JR, Prazeres J, Sacramento GA, Ko AI, Maia M, 303	  
et al. Ocular Findings in Infants With Microcephaly Associated With Presumed Zika 304	  
Virus Congenital Infection in Salvador, Brazil. JAMA Ophthalmol 2016. 305	  
8.  Ventura CV, Maia M, Ventura BV, Linden VV, Araujo EB, Ramos RC, et al. 306	  
Ophthalmological findings in infants with microcephaly and presumable intra-uterus 307	  
Zika virus infection. Arq Bras Oftalmol 2016; 79: 1-3. 308	  
9.  Brasil P, Pereira JP, Jr., Raja Gabaglia C, Damasceno L, Wakimoto M, Ribeiro 309	  
Nogueira RM, et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro - 310	  
Preliminary Report. N Engl J Med 2016. 311	  
10.  Calvet G, Aguiar RS, Melo AS, Sampaio SA, de Filippis I, Fabri A, et al. Detection 312	  
and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in 313	  
Brazil: a case study. Lancet Infect Dis 2016; 16:653-60 314	  
	   14	  
11. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika Virus and Birth Defects 315	  
- Reviewing the Evidence for Causality. N Engl J Med 2016; 1981-7. 316	  
12. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic 317	  
and serologic properties of Zika virus associated with an epidemic, Yap State, 318	  
Micronesia, 2007. Emerg Infect Dis 2008; 14: 1232-9. 319	  
13.  Musso D, Gubler DJ. Zika Virus. Clin Microbiol Rev 2016; 29: 487-524. 320	  
14.  Staples JE, Dziuban EJ, Fischer M, Cragan JD, Rasmussen SA, Cannon MJ, et al. 321	  
Interim Guidelines for the Evaluation and Testing of Infants with Possible Congenital 322	  
Zika Virus Infection - United States, 2016. MMWR Morb Mortal Wkly Rep 2016; 65: 323	  
63-7. 324	  
15.  Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton 325	  
growth chart for preterm infants. BMC Pediatr 2013; 13: 59. 326	  
16.  Faye O, Dupressoir A, Weidmann M, Ndiaye M, Alpha Sall A. One-step RT-PCR for 327	  
detection of Zika virus. J Clin Virol 2008; 43: 96-101. 328	  
17.  Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and 329	  
typing of dengue viruses from clinical samples by using reverse transcriptase-330	  
polymerase chain reaction. J Clin Microbiol 1992; 30: 545-51. 331	  
18.  Lanciotti RS, Kosoy OL, Laven JJ, Panella AJ, Velez JO, Lambert AJ, et al. 332	  
Chikungunya virus in US travelers returning from India, 2006. Emerg Infect Dis 2007; 333	  
13: 764-7. 334	  
19.  Castanha PM, Cordeiro MT, Martelli CM, Souza WV, Marques ET, Jr., Braga C. 335	  
Force of infection of dengue serotypes in a population-based study in the northeast of 336	  
Brazil. Epidemiol Infect 2013; 141: 1080-8. 337	  
	   15	  
20.  Cordeiro MT, Schatzmayr HG, Nogueira RM, Oliveira VF, Melo WT, Carvalho EF. 338	  
Dengue and dengue hemorrhagic fever in the State of Pernambuco, 1995-2006. Rev 339	  
Soc Bras Med Trop 2007; 40: 605-11. 340	  
21. Teixeira MG, Siqueira JB, Jr., Ferreira GL, Bricks L, Joint G. Epidemiological trends 341	  
of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. 342	  
PLoS Negl Trop Dis 2013; 7: e2520. 343	  
22. Cordeiro MT, Silva AM, Brito CA, Nascimento EJ, Magalhaes MC, Guimaraes GF, et 344	  
al. Characterization of a dengue patient cohort in Recife, Brazil. Am J Trop Med Hyg  345	  
2007; 77: 1128-34. 346	  
23.  Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, et al. The 347	  
management of encephalitis: clinical practice guidelines by the Infectious Diseases 348	  
Society of America. Clin Infect Dis 2008; 47: 303-27. 349	  
 350	  
 351	  
 352	  
 353	  
 354	  
 355	  
 356	  
 357	  
 358	  
 359	  
 360	  
 361	  
 362	  
	   16	  
Figure Legends 363	  
 364	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